Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARTV
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARTV
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ALLO ARTV CDXS
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARTV
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ARTV
Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply
From Artiva Biotherapeutics, Inc.
Via Business Wire
Artiva Biotherapeutics Appoints Two New Independent Members to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.